Today: 10 June 2026
Browse Category

NASDAQ:ROIV 11 December 2025 - 20 May 2026

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
20 May 2026
···
Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next

Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next

Roivant Sciences shares surged 22% to $25.82 Friday after the company reported positive Phase 2 data for brepocitinib in cutaneous sarcoidosis and filed for U.S. approval in dermatomyositis. Trading volume exceeded 24 million shares. Roivant posted a quarterly loss of $313.7 million on $2 million in revenue, with $4.5 billion in cash and equivalents.
8 February 2026
·
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
7 February 2026
··
Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts

Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts

Roivant Sciences shares climbed near $21.50 on December 11, approaching 52-week highs after the company’s Investor Day outlined plans for at least three product launches and four regulatory filings by 2028. The stock has gained about 85% over six months, pushing market value to roughly $15 billion. Management advanced timelines for key drug programs, including brepocitinib and IMVT-1402.
11 December 2025

Stock Market Today

  • VS Media Shares Surge Over 300% Premarket on S T Meng Debt-to-Equity Swap
    June 10, 2026, 9:59 AM EDT. VS Media Holdings Limited's shares soared 316.57% to $3.43 in premarket Nasdaq trading on June 10, 2026, following a $3.8 million debt-to-equity conversion agreement with Singapore-linked S T Meng Pte. Ltd. This deal raised VS Media's voting stake in S T Meng to 41.52% from 19%. Despite the dramatic share price rise, VS Media remains a micro-cap firm with a market cap of about $2.29 million and posted a net loss in 2025, raising concerns about its sustainability. The stock's premarket surge reflects investor interest in the company's expanding exposure, but VS Media has yet to generate revenue from its new AI Smart Living initiatives.

Latest articles

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

10 June 2026
Rigetti Computing plunged 9.55% to $19.69 Tuesday and dipped further premarket after director Ray O. Johnson filed to sell 122,188 shares worth $2.6 million, testing investor confidence following a recent rally on news of a potential $100 million U.S. Commerce Department quantum-computing award, with traders watching for binding funding terms amid ongoing volatility.
PATH slips again, investors keep questioning AI automation bet

PATH slips again, investors keep questioning AI automation bet

10 June 2026
UiPath shares slid 3.76% to $10.75 and dropped another 1.49% pre-market as investors focused on slowing annual recurring revenue growth—up 12% to $1.901 billion versus 17% revenue growth—raising doubts about AI automation’s impact on recurring sales; second-quarter ARR guidance of $1.929–$1.934 billion is now the key number for PATH’s stock direction.
Go toTop